Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4412)
All Articles published online
|
Apr 21, 2008 (publication date) through May 1, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: |
Li JK, Yu L, Shen Y, Zhou LS, Wang YC, Zhang JH. Inhibition of CXCR4 activity with AMD3100 decreases invasion of human colorectal cancer cells |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v14/i15/2308.htm |
| Number | Citing Articles |
| 1 |
Yingzheng Weng, Jiangjie Lou, Xiaowei Liu, Senna Lin, Chenkai Xu, Changqing Du, Lijiang Tang. Effects of high glucose on proliferation and function of circulating fibrocytes: Involvement of CXCR4/SDF‑1 axis. International Journal of Molecular Medicine 2019; doi: 10.3892/ijmm.2019.4260
|
| 2 |
Stephanie Lemmo Ham, Pradip Shahi Thakuri, Madison Plaster, Jun Li, Kathryn E. Luker, Gary D. Luker, Hossein Tavana. Three-dimensional tumor model mimics stromal - breast cancer cells signaling. Oncotarget 2018; 9(1): 249 doi: 10.18632/oncotarget.22922
|
| 3 |
Wen‐Bin Zhu, Zhi‐Feng Zhao, Xin Zhou. AMD3100 inhibits epithelial–mesenchymal transition, cell invasion, and metastasis in the liver and the lung through blocking the SDF‐1α/CXCR4 signaling pathway in prostate cancer. Journal of Cellular Physiology 2019; 234(7): 11746 doi: 10.1002/jcp.27831
|
| 4 |
Xianping Shi, Xin Chen, Xiaofen Li, Xiaoying Lan, Chong Zhao, Shouting Liu, Hongbiao Huang, Ningning Liu, Siyan Liao, Wenbin Song, Ping Zhou, Shunqing Wang, Li Xu, Xuejun Wang, Q. Ping Dou, Jinbao Liu. Gambogic Acid Induces Apoptosis in Imatinib-Resistant Chronic Myeloid Leukemia Cells via Inducing Proteasome Inhibition and Caspase-Dependent Bcr-Abl Downregulation. Clinical Cancer Research 2014; 20(1): 151 doi: 10.1158/1078-0432.CCR-13-1063
|
| 5 |
Tao Wang, Yanfang Mi, Linping Pian, Ping Gao, Hong Xu, Yuling Zheng, Xiaoyan Xuan. RETRACTED ARTICLE: RNAi targeting CXCR4 inhibits proliferation and invasion of esophageal carcinoma cells. Diagnostic Pathology 2013; 8(1) doi: 10.1186/1746-1596-8-104
|
| 6 |
Hashem O. Alsaab, Atiah H. Almalki. Anti-HSP70 alleviates cell migration and proliferation in colorectal cancer cells (CRC) by targeting CXCR4 (in vitro study). Medical Oncology 2023; 40(9) doi: 10.1007/s12032-023-02122-6
|
| 7 |
A.N. Gordon-Weeks, S.Y. Lim, A.E. Yuzhalin, K. Jones, R. Muschel. Macrophage migration inhibitory factor: A key cytokine and therapeutic target in colon cancer. Cytokine & Growth Factor Reviews 2015; 26(4): 451 doi: 10.1016/j.cytogfr.2015.03.002
|
| 8 |
Masaichi Ogawa, Michiaki Watanabe, Takuo Hasegawa, Kohei Ichihara, Kazuhiko Yoshida, Katsuhiko Yanaga. Expression of CXCR-4 and IDO in human colorectal cancer: An immunohistochemical approach. Molecular and Clinical Oncology 2017; 6(5): 701 doi: 10.3892/mco.2017.1207
|
| 9 |
Hannelien Verbeke, Sofie Struyf, Geneviève Laureys, Jo Van Damme. The expression and role of CXC chemokines in colorectal cancer. Cytokine & Growth Factor Reviews 2011; 22(5-6): 345 doi: 10.1016/j.cytogfr.2011.09.002
|
| 10 |
Thomas Seufferlein, Johann Ahn, Denis Krndija, Ulrike Lother, Guido Adler, Götz von Wichert. Tumor biology and cancer therapy – an evolving relationship. Cell Communication and Signaling 2009; 7(1) doi: 10.1186/1478-811X-7-19
|
| 11 |
STEFAN LANGHAMMER. Rationale for the design of an oncology trial using a generic targeted therapy multi-drug regimen for NSCLC patients without treatment options (Review). Oncology Reports 2013; 30(4): 1535 doi: 10.3892/or.2013.2631
|
| 12 |
Beibei Zhai, Xiaofeng Zhang, Bin Sun, Lu Cao, Linlin Zhao, Jun Li, Naijian Ge, Lei Chen, Haihua Qian, Zhengfeng Yin. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK. Tumor Biology 2016; 37(6): 8047 doi: 10.1007/s13277-015-4707-1
|
| 13 |
Yao-ping Li, Jing Pang, Sheng Gao, Peng-yu Bai, Wen-da Wang, Pengzhou Kong, Yongping Cui. Role of CXCR4 and SDF1 as prognostic factors for survival and the association with clinicopathology in colorectal cancer: A systematic meta-analysis. Tumor Biology 2017; 39(6): 101042831770620 doi: 10.1177/1010428317706206
|
| 14 |
Moneeb Ehtesham, Elliot Min, Neil M. Issar, Rebecca A. Kasl, Imad S. Khan, Reid C. Thompson. The role of the CXCR4 cell surface chemokine receptor in glioma biology. Journal of Neuro-Oncology 2013; 113(2): 153 doi: 10.1007/s11060-013-1108-4
|
| 15 |
Pedro Linares-Clemente, Diana Aguilar-Morante, Ismael Rodríguez-Prieto, Gema Ramírez, Carmen de Torres, Vicente Santamaría, Diego Pascual-Vaca, Ana Colmenero-Repiso, Francisco M. Vega, Jaume Mora, Rosa Cabello, Catalina Márquez, Eloy Rivas, Ricardo Pardal. Neural crest derived progenitor cells contribute to tumor stroma and aggressiveness in stage 4/M neuroblastoma. Oncotarget 2017; 8(52): 89775 doi: 10.18632/oncotarget.21128
|
| 16 |
Briana Mason, Corey Calhoun, Victoria Woytowicz, Latifa Pina, Roshninder Kanda, Curtis Dunn, Antonio Alves, S. Tiffany Donaldson, Pavel I. Ortinski. CXCR4 inhibition with AMD3100 attenuates amphetamine induced locomotor activity in adolescent Long Evans male rats. PLOS ONE 2021; 16(3): e0247707 doi: 10.1371/journal.pone.0247707
|
| 17 |
Hossein Jadvar, Xiaoyuan Chen, Weibo Cai, Umar Mahmood. Radiotheranostics in Cancer Diagnosis and Management. Radiology 2018; 286(2): 388 doi: 10.1148/radiol.2017170346
|
| 18 |
Victoria Vinader, Yousef Al-Saraireh, Helen L. Wiggins, Joshua Z. Rappoport, Steve D. Shnyder, Laurence H. Patterson, Kamyar Afarinkia. An agarose spot chemotaxis assay for chemokine receptor antagonists. Journal of Pharmacological and Toxicological Methods 2011; 64(3): 213 doi: 10.1016/j.vascn.2011.01.004
|
| 19 |
Erik De Clercq. The AMD3100 story: The path to the discovery of a stem cell mobilizer (Mozobil). Biochemical Pharmacology 2009; 77(11): 1655 doi: 10.1016/j.bcp.2008.12.014
|
| 20 |
Yanpeng Ding, Jiayu Fang, Mengge Chen, Yulian Xu, Nuomin Liu, Sha Fang, Wenbin Xiang, Rui Chen, Chaoyan Wu, Haijun Yu. MT1X is an oncogene and indicates prognosis in ccRCC. Bioscience Reports 2022; 42(10) doi: 10.1042/BSR20221128
|
| 21 |
Hossein Khorramdelazad, Kowsar Bagherzadeh, Ali Rahimi, Elaheh Safari, Gholamhossein Hassanshahi, Majid Khoshmirsafa, Milad Karimi, Mahdi Mohammadi, Ali Darehkordi, Reza Falak. Antitumor activities of a novel fluorinated small molecule (A1) in CT26 colorectal cancer cells: molecular docking and in vitro studies. Journal of Biomolecular Structure and Dynamics 2023; : 1 doi: 10.1080/07391102.2023.2256406
|
| 22 |
Ragini Yeeravalli, Amitava Das. Molecular mediators of breast cancer metastasis. Hematology/Oncology and Stem Cell Therapy 2021; 14(4): 275 doi: 10.1016/j.hemonc.2021.02.002
|
| 23 |
Sheng Yin, Chunyu Xia, Yashi Wang, Dandan Wan, Jingdong Rao, Xian Tang, Jiaojie Wei, Xuhui Wang, Man Li, Zhirong Zhang, Ji Liu, Qin He. Dual receptor recognizing liposomes containing paclitaxel and hydroxychloroquine for primary and metastatic melanoma treatment via autophagy-dependent and independent pathways. Journal of Controlled Release 2018; 288: 148 doi: 10.1016/j.jconrel.2018.08.015
|
| 24 |
Orit Jacobson, Ido D. Weiss, Dale O. Kiesewetter, Joshua M. Farber, Xiaoyuan Chen. PET of Tumor CXCR4 Expression with 4-18F-T140. Journal of Nuclear Medicine 2010; 51(11): 1796 doi: 10.2967/jnumed.110.079418
|
| 25 |
C. Du, Y. Yao, W. Xue, W.-G. Zhu, Y. Peng, J. Gu. The expression of chemokine receptors CXCR3 and CXCR4 in predicting postoperative tumour progression in stages I-II colon cancer: a retrospective study. BMJ Open 2014; 4(8): e005012 doi: 10.1136/bmjopen-2014-005012
|
| 26 |
Barbara Mognetti, Giuseppe La Montagna, Maria Giulia Perrelli, Pasquale Pagliaro, Claudia Penna. Bone marrow mesenchymal stem cells increase motility of prostate cancer cells via production of stromal cell‐derived factor‐1α. Journal of Cellular and Molecular Medicine 2013; 17(2): 287 doi: 10.1111/jcmm.12010
|
| 27 |
Sara Tomei, Ola Ibnaof, Shilpa Ravindran, Soldano Ferrone, Cristina Maccalli. Cancer Stem Cells Are Possible Key Players in Regulating Anti-Tumor Immune Responses: The Role of Immunomodulating Molecules and MicroRNAs. Cancers 2021; 13(7): 1674 doi: 10.3390/cancers13071674
|
| 28 |
Malene Broholm, Thea Helene Degett, Sara Furbo, Anne-Marie Kanstrup Fiehn, Mustafa Bulut, Thomas Litman, Jens Ole Eriksen, Jesper T. Troelsen, Lise Mette Rahbek Gjerdrum, Ismail Gögenur. Colonic Stent as Bridge to Surgery for Malignant Obstruction Induces Gene Expressional Changes Associated with a More Aggressive Tumor Phenotype. Annals of Surgical Oncology 2021; 28(13): 8519 doi: 10.1245/s10434-021-10226-4
|
| 29 |
Stefania Gelmini, Monica Mangoni, Francesca Castiglione, Cristina Beltrami, Annalisa Pieralli, Karin Louise Andersson, Massimiliano Fambrini, Gian Luigi Taddei, Mario Serio, Claudio Orlando. The CXCR4/CXCL12 axis in endometrial cancer. Clinical & Experimental Metastasis 2009; 26(3): 261 doi: 10.1007/s10585-009-9240-4
|
| 30 |
Fang Wen, Xiaona Lu, Wenjie Huang, Xiaoxue Chen, Shuai Ruan, SuPing Gu, Peixing Gu, Ye Li, Jiatong Liu, Shenlin Liu, Peng Shu. Characteristics of immunophenotypes and immunological in tumor microenvironment and analysis of immune implication of CXCR4 in gastric cancer. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-08622-1
|
| 31 |
Cynthia Lee Richard, Jonathan Blay. CXCR4 in Cancer and Its Regulation by PPARγ. PPAR Research 2008; 2008: 1 doi: 10.1155/2008/769413
|
| 32 |
TIAN-BAO WANG, BAO-GUANG HU, DA-WEI LIU, HAN-PING SHI, WEN-GUANG DONG. The influence of lentivirus-mediated CXCR4 RNA interference on hepatic metastasis of colorectal cancer. International Journal of Oncology 2014; 44(6): 1861 doi: 10.3892/ijo.2014.2348
|
| 33 |
Tali Voloshin, Svetlana Gingis-Velitski, Rotem Bril, Liat Benayoun, Michal Munster, Chloe Milsom, Shan Man, Robert S. Kerbel, Yuval Shaked. G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist. Blood 2011; 118(12): 3426 doi: 10.1182/blood-2010-11-320812
|
| 34 |
Orit Jacobson, Ido D. Weiss, Lawrence Szajek, Joshua M. Farber, Dale O. Kiesewetter. 64Cu-AMD3100—A novel imaging agent for targeting chemokine receptor CXCR4. Bioorganic & Medicinal Chemistry 2009; 17(4): 1486 doi: 10.1016/j.bmc.2009.01.014
|
| 35 |
Bo Shen, Ma-Qing Zheng, Jian-Wei Lu, Qian Jiang, Tai-Hong Wang, Xin-En Huang. CXCL12-CXCR4 Promotes Proliferation and Invasion of Pancreatic Cancer Cells. Asian Pacific Journal of Cancer Prevention 2013; 14(9): 5403 doi: 10.7314/APJCP.2013.14.9.5403
|
| 36 |
Laura N. Zamproni, Daniela Teixeira, Amanda A. Alliegro, Ieda L. Maugéri, Anne des Rieux, Marimelia A. Porcionatto. Decreased viability and neurite length in neural cells treated with chitosan-dextran sulfate nanocomplexes. NeuroToxicology 2020; 76: 33 doi: 10.1016/j.neuro.2019.10.001
|
| 37 |
Dongzhi Hu, Changzheng Du, Weicheng Xue, Fangyuan Dou, Yunfeng Yao, Jin Gu. The expression of chemokine receptors CCR6, CXCR2 and CXCR4 is not organ‐specific for distant metastasis in colorectal cancer: a comparative study. Histopathology 2013; 63(2): 167 doi: 10.1111/his.12127
|
| 38 |
K. Kim, H. Y. Kim, H. K. Cho, K. H. Kim, J. Cheong. The SDF-1 /CXCR4 axis induces the expression of fatty acid synthase via sterol regulatory element-binding protein-1 activation in cancer cells. Carcinogenesis 2010; 31(4): 679 doi: 10.1093/carcin/bgp329
|
| 39 |
KANG SU CHO, SO JUNG YOON, JOO YONG LEE, NAM HOON CHO, YOUNG DEUK CHOI, YUN SEOB SONG, SUNG JOON HONG. Inhibition of tumor growth and histopathological changes following treatment with a chemokine receptor CXCR4 antagonist in a prostate cancer xenograft model. Oncology Letters 2013; 6(4): 933 doi: 10.3892/ol.2013.1515
|
| 40 |
Zhi-Yu Song, Zu-Hua Gao, Xian-Jun Qu. A review of CXCR4/CXCL12 axis in colorectal cancer. Biomedicine & Aging Pathology 2014; 4(3): 285 doi: 10.1016/j.biomag.2014.06.001
|
| 41 |
Yan Wang, Wei-Cheng Liang, Wen-Liang Pan, Wai-Kit Law, Jian-Shu Hu, Denis Tsz-Ming Ip, Mary Miu-Yee Waye, Tzi-Bun Ng, David Chi-Cheong Wan. Silibinin, a novel chemokine receptor type 4 antagonist, inhibits chemokine ligand 12-induced migration in breast cancer cells. Phytomedicine 2014; 21(11): 1310 doi: 10.1016/j.phymed.2014.06.018
|
| 42 |
Kazem Zibara, Zahraa Awada, Leila Dib, Jamal El-Saghir, Sara Al-Ghadban, Aida Ibrik, Nabil El-Zein, Marwan El-Sabban. Anti-angiogenesis therapy and gap junction inhibition reduce MDA-MB-231 breast cancer cell invasion and metastasis in vitro and in vivo. Scientific Reports 2015; 5(1) doi: 10.1038/srep12598
|
| 43 |
Zhenzhen Zhou, Huan Deng, Wei Yan, Min Luo, Wei Tu, Yujia Xia, Jiayi He, Ping Han, Yu Fu, De'an Tian, Eric Asselin. AEG-1 Promotes Anoikis Resistance and Orientation Chemotaxis in Hepatocellular Carcinoma Cells. PLoS ONE 2014; 9(6): e100372 doi: 10.1371/journal.pone.0100372
|
| 44 |
KAWIN LEELAWAT, SIRIPORN KEERATICHAMROEN, SURANG LEELAWAT, RUTAIWAN TOHTONG. CD24 induces the invasion of cholangiocarcinoma cells by upregulating CXCR4 and increasing the phosphorylation of ERK1/2. Oncology Letters 2013; 6(5): 1439 doi: 10.3892/ol.2013.1587
|
| 45 |
C. L. Lu, Y. Ji, D. Ge, J. Guo, J. Y. Ding. The expression of CXCR4 and its relationship with matrix metalloproteinase-9/vascular endothelial growth factor in esophageal squamous cell cancer. Diseases of the Esophagus 2011; 24(4): 283 doi: 10.1111/j.1442-2050.2010.01135.x
|
| 46 |
Yuki Iwasaki, Hirofumi Akari, Tsutomu Murakami, Sei Kumakura, Md. Zahidunnabi Dewan, Mikiro Yanaka, Naoki Yamamoto. Efficient inhibition of SDF‐1α‐mediated chemotaxis and HIV‐1 infection by novel CXCR4 antagonists. Cancer Science 2009; 100(4): 778 doi: 10.1111/j.1349-7006.2009.01104.x
|
| 47 |
Katharina Helene Susek, Maria Karvouni, Evren Alici, Andreas Lundqvist. The Role of CXC Chemokine Receptors 1–4 on Immune Cells in the Tumor Microenvironment. Frontiers in Immunology 2018; 9 doi: 10.3389/fimmu.2018.02159
|
| 48 |
Aïssata Aimée Goïta, Dominique Guenot. Colorectal Cancer: The Contribution of CXCL12 and Its Receptors CXCR4 and CXCR7. Cancers 2022; 14(7): 1810 doi: 10.3390/cancers14071810
|
| 49 |
Fang-Ting Duan, Feng Qian, Ke Fang, Kang-Yu Lin, Wen-Tao Wang, Yue-Qin Chen. miR-133b, a muscle-specific microRNA, is a novel prognostic marker that participates in the progression of human colorectal cancer via regulation of CXCR4 expression. Molecular Cancer 2013; 12(1) doi: 10.1186/1476-4598-12-164
|
| 50 |
Bruna Karina Banin Hirata, Julie Massayo Maeda Oda, Roberta Losi Guembarovski, Carolina Batista Ariza, Carlos Eduardo Coral de Oliveira, Maria Angelica Ehara Watanabe. Molecular Markers for Breast Cancer: Prediction on Tumor Behavior. Disease Markers 2014; 2014: 1 doi: 10.1155/2014/513158
|
| 51 |
|
| 52 |
D. Yoshida, K Koketshu, R. Nomura, A. Teramoto. The CXCR4 antagonist AMD3100 suppresses hypoxia-mediated growth hormone production in GH3 rat pituitary adenoma cells. Journal of Neuro-Oncology 2010; 100(1): 51 doi: 10.1007/s11060-010-0152-6
|
| 53 |
Ha-Yon Kim, Ji-Young Hwang, Seong-Woo Kim, Hyo-Jin Lee, Hwan-Jung Yun, Samyong Kim, Deog-Yeon Jo. The CXCR4 Antagonist AMD3100 Has Dual Effects on Survival and Proliferation of Myeloma CellsIn Vitro. Cancer Research and Treatment 2010; 42(4): 225 doi: 10.4143/crt.2010.42.4.225
|
| 54 |
Orit Jacobson, Ido D. Weiss, Lawrence P. Szajek, Gang Niu, Ying Ma, Dale O. Kiesewetter, Amnon Peled, Henry S. Eden, Joshua M. Farber, Xiaoyuan Chen. Improvement of CXCR4 tracer specificity for PET imaging. Journal of Controlled Release 2012; 157(2): 216 doi: 10.1016/j.jconrel.2011.09.076
|
| 55 |
Young Hwa Kim, Yong Won Choi, Jeonghun Lee, Euy Young Soh, Jang-Hee Kim, Tae Jun Park. Senescent tumor cells lead the collective invasion in thyroid cancer. Nature Communications 2017; 8(1) doi: 10.1038/ncomms15208
|